The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors
Tumour markers have no established role in the monitoring of the course of metastatic breast cancer during antineoplastic therapy, yet cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) are commonly used in clinical practice to aid in the early detection of progression of disease (PD)....
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2022-09-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/the-prognostic-role-of-variations-in-tumour-markers-cea-ca15-3-in-patients-with-metastatic-breast-cancer-treated-with-cdk4-6-inhibitors |
| _version_ | 1828148975831613440 |
|---|---|
| author | Federico Sottotetti Elisa Ferraris Barbara Tagliaferri Raffaella Palumbo Erica Quaquarini Cristina Teragni Emanuela Balletti Claudia Leli Andrea Premoli Ludovica Mollica Silvia Puglisi Silvia Sardi Alberto Malovini Paolo Pedrazzoli Antonio Bernardo |
| author_facet | Federico Sottotetti Elisa Ferraris Barbara Tagliaferri Raffaella Palumbo Erica Quaquarini Cristina Teragni Emanuela Balletti Claudia Leli Andrea Premoli Ludovica Mollica Silvia Puglisi Silvia Sardi Alberto Malovini Paolo Pedrazzoli Antonio Bernardo |
| author_sort | Federico Sottotetti |
| collection | DOAJ |
| description | Tumour markers have no established role in the monitoring of the course of metastatic breast cancer during antineoplastic therapy, yet cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) are commonly used in clinical practice to aid in the early detection of progression of disease (PD). In our multicentre, prospective, real-life study, we enrolled 142 consecutive patients with advanced breast cancer receiving endocrine therapy in combination with a CDK4/6 inhibitor from January 2017 to October 2020; 75 patients had PD at the time of database closure. We measured serum marker concentrations at regular 4-month intervals together with radiological tumour response assessments and in cases of clinical suspicion of PD. Appropriate descriptive and inferential statistical methods were used to analyse serum marker level trends amongst prespecified subgroups and at specific time points (baseline, best radiologically documented tumour response and first detection of PD) in the subpopulation of patients with PD at the time of database closure. Notably, the median time from treatment initiation to best tumour response was 4.4 months. We evaluated the presence of an association between baseline CA15.3 and CEA levels and prespecified clinical characteristics but found no clinically meaningful correlation. We assessed marker level variations at the time of best radiologically documented disease response and PD: in the subgroup of patients who responded to treatment before progressing, we detected a statistically significant correlation with tumour marker variation between the time of best response and progression; this finding was not confirmed in the subgroup of patients that did not benefit from treatment. In conclusion, serum tumour marker flares can be useful in the early diagnosis of PD but should not be used as the sole factor prompting a change in treatment strategy without radiological confirmation.
This article is part of the Tackling clinical complexity in breast cancer Special Issue: https://www.drugsincontext.com/special_issues/tackling-clinical-complexity-in-breast-cancer/
|
| first_indexed | 2024-04-11T21:24:13Z |
| format | Article |
| id | doaj.art-9e1c435f3c4a4e3a91123dc791ec111f |
| institution | Directory Open Access Journal |
| issn | 1740-4398 |
| language | English |
| last_indexed | 2024-04-11T21:24:13Z |
| publishDate | 2022-09-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-9e1c435f3c4a4e3a91123dc791ec111f2022-12-22T04:02:31ZengBioExcel Publishing LtdDrugs in Context1740-43982022-09-011111010.7573/dic.2022-1-3The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitorsFederico SottotettiElisa FerrarisBarbara TagliaferriRaffaella PalumboErica QuaquariniCristina TeragniEmanuela BallettiClaudia LeliAndrea PremoliLudovica MollicaSilvia PuglisiSilvia SardiAlberto MaloviniPaolo PedrazzoliAntonio BernardoTumour markers have no established role in the monitoring of the course of metastatic breast cancer during antineoplastic therapy, yet cancer antigen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) are commonly used in clinical practice to aid in the early detection of progression of disease (PD). In our multicentre, prospective, real-life study, we enrolled 142 consecutive patients with advanced breast cancer receiving endocrine therapy in combination with a CDK4/6 inhibitor from January 2017 to October 2020; 75 patients had PD at the time of database closure. We measured serum marker concentrations at regular 4-month intervals together with radiological tumour response assessments and in cases of clinical suspicion of PD. Appropriate descriptive and inferential statistical methods were used to analyse serum marker level trends amongst prespecified subgroups and at specific time points (baseline, best radiologically documented tumour response and first detection of PD) in the subpopulation of patients with PD at the time of database closure. Notably, the median time from treatment initiation to best tumour response was 4.4 months. We evaluated the presence of an association between baseline CA15.3 and CEA levels and prespecified clinical characteristics but found no clinically meaningful correlation. We assessed marker level variations at the time of best radiologically documented disease response and PD: in the subgroup of patients who responded to treatment before progressing, we detected a statistically significant correlation with tumour marker variation between the time of best response and progression; this finding was not confirmed in the subgroup of patients that did not benefit from treatment. In conclusion, serum tumour marker flares can be useful in the early diagnosis of PD but should not be used as the sole factor prompting a change in treatment strategy without radiological confirmation. This article is part of the Tackling clinical complexity in breast cancer Special Issue: https://www.drugsincontext.com/special_issues/tackling-clinical-complexity-in-breast-cancer/ https://www.drugsincontext.com/the-prognostic-role-of-variations-in-tumour-markers-cea-ca15-3-in-patients-with-metastatic-breast-cancer-treated-with-cdk4-6-inhibitorsbreast cancercdk4/6 inhibitorstumour markers |
| spellingShingle | Federico Sottotetti Elisa Ferraris Barbara Tagliaferri Raffaella Palumbo Erica Quaquarini Cristina Teragni Emanuela Balletti Claudia Leli Andrea Premoli Ludovica Mollica Silvia Puglisi Silvia Sardi Alberto Malovini Paolo Pedrazzoli Antonio Bernardo The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors Drugs in Context breast cancer cdk4/6 inhibitors tumour markers |
| title | The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors |
| title_full | The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors |
| title_fullStr | The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors |
| title_full_unstemmed | The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors |
| title_short | The prognostic role of variations in tumour markers (CEA, CA15.3) in patients with metastatic breast cancer treated with CDK4/6 inhibitors |
| title_sort | prognostic role of variations in tumour markers cea ca15 3 in patients with metastatic breast cancer treated with cdk4 6 inhibitors |
| topic | breast cancer cdk4/6 inhibitors tumour markers |
| url | https://www.drugsincontext.com/the-prognostic-role-of-variations-in-tumour-markers-cea-ca15-3-in-patients-with-metastatic-breast-cancer-treated-with-cdk4-6-inhibitors |
| work_keys_str_mv | AT federicosottotetti theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT elisaferraris theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT barbaratagliaferri theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT raffaellapalumbo theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT ericaquaquarini theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT cristinateragni theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT emanuelaballetti theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT claudialeli theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT andreapremoli theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT ludovicamollica theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT silviapuglisi theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT silviasardi theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT albertomalovini theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT paolopedrazzoli theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT antoniobernardo theprognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT federicosottotetti prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT elisaferraris prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT barbaratagliaferri prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT raffaellapalumbo prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT ericaquaquarini prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT cristinateragni prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT emanuelaballetti prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT claudialeli prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT andreapremoli prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT ludovicamollica prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT silviapuglisi prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT silviasardi prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT albertomalovini prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT paolopedrazzoli prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors AT antoniobernardo prognosticroleofvariationsintumourmarkersceaca153inpatientswithmetastaticbreastcancertreatedwithcdk46inhibitors |